Svelte Medical Systems, Inc. Release: World’s First Integrated Delivery System Meets All Endpoints In The Direct II Randomized, Controlled Drug-Eluting Coronary Stent Study

WASHINGTON, D.C.--(BUSINESS WIRE)--Svelte Medical Systems today reported that its drug-eluting coronary stent Integrated Delivery System (IDS), a new approach to Percutaneous Coronary Intervention (PCI) and the first advance in coronary stent delivery in nearly 20-years, met all DIRECT II study 6-month angiographic and clinical endpoints. The IDS also exhibited reduced procedure and device times, with trends toward reduced fluoroscopy time and contrast use, confirming results seen in prior studies in which the IDS demonstrated procedural time and cost savings.

Help employers find you! Check out all the jobs and post your resume.